论文部分内容阅读
目的:探讨埃罗替尼靶向治疗前后非小细胞肺癌患者外周血CD4+、CD8+和CD56+的表达及其临床意义。方法:流式技术检测30例EGFR突变的非小细胞肺癌患者埃罗替尼一线靶向治疗前后,外周血T细胞亚群的表达情况及疗效。结果:靶向治疗1个月后,与治疗前相比较非小细胞肺癌患者外周血T细胞亚群CD4+、CD8+以及CD56+表达数量有统计学差异(P<0.05)。其中,CD4+表达上升,CD8+和CD56+表达下降。结论:埃罗替尼靶向治疗可以改善非小细胞肺癌患者细胞免疫功能,观察外周血T细胞亚群表达情况有助于评价埃罗替尼靶向治疗的疗效和预后。
Objective: To investigate the expression of CD4 +, CD8 + and CD56 + in peripheral blood of patients with non-small cell lung cancer before and after erlotinib-targeted therapy and its clinical significance. Methods: Flow cytometry was used to detect the expression of T lymphocyte subsets in peripheral blood before and after the first line of erlotinib therapy in 30 NSCLC patients with EGFR mutation. Results: After one month of targeted therapy, the numbers of CD4 +, CD8 + and CD56 + T cells in peripheral blood of patients with non-small cell lung cancer were significantly different from those before treatment (P <0.05). Among them, CD4 + expression increased, CD8 + and CD56 + expression decreased. Conclusion: Erlotinib can improve the cellular immune function in patients with non-small cell lung cancer. The observation of the expression of T lymphocyte subsets in peripheral blood is helpful to evaluate the efficacy and prognosis of erlotinib-targeted therapy.